Abigail Brooks

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

Catch up on the latest in hepatology, from bulevirtide's FDA approval for hepatitis delta to expert perspectives on new and emerging therapies in PBC, PSC, and MASLD.

Catch up on Q2 GI headlines you may have missed, including an expanded FDA approval for linaclotide, a submission for risankizumab SC induction in Crohn's, and more.

Catch up on Q2 hepatology headlines, including the historic FDA approval of bulevirtide for hepatitis delta, new data on bepirovirsen for HBV, and more.

The FDA recently approved the first generic baloxavir tablet for influenza treatment and postexposure prophylaxis in patients aged 5 years or older.

Clinicians discuss DKA risk, sick day plans, CGM use, and ketone testing in primary care.

Eden Miller, DO, and panelists discuss DKA recognition gaps, ketone testing barriers, and the future of dual glucose-ketone sensing.

Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.

Freenome reported updated SimpleScreen CRC results showing 80.4% colorectal cancer sensitivity and 90% specificity.

AI-generated portal message drafts often missed clinical context and required physician editing in a Dartmouth analysis.